Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate CancerMeng-Lei Zhu, Natasha Kyprianou|Cancer Research|2010Cited by 350
Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate CancerBarbara E. Kahn, Natasha Kyprianou|International Journal of Biological Sciences|2014Cited by 110
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancerJohn T. Isaacs, Tomas Leanderson, David Z. Qian et al.|The Prostate|2006Cited by 87
Novel Pharmacologic Targeting of Tight Junctions and Focal Adhesions in Prostate Cancer CellsPatrick J. Hensley, Natasha Kyprianou|PLoS ONE|2014Cited by 35
Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate TumorigenesisHong Pu, Natasha Kyprianou|Endocrinology|2017Cited by 28